IL-DURAVANT
22.2.2021 13:02:06 CET | Business Wire | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced the acquisition of Votech GS B.V. (“Votech”), a leading manufacturer of bag filling machines, palletizer machines, stretch hood machines and pallet transport systems headquartered in Reusel, The Netherlands. Votech will join forces with Fischbein International, a Duravant Operating Company, to serve their global customer base.
The combination of Votech’s expertise in bag management and palletizing and Fischbein’s portfolio of bag sealing and sewing equipment creates a complementary fit between the two companies.
“There is a very complementary relationship between our two organizations,” said Olivier Hancotte, VP and General Manager of Fischbein. “We’re thrilled to work closely with the Votech team to create a broader product offering for both companies’ customers. Fischbein and Votech equipment will both be available through the Fischbein global sales team.”
This partnership brings together two global engineered equipment leaders and extends Duravant’s ability to serve customers and partners in over 190 countries worldwide across multiple sectors including agriculture, industrials, fruit and vegetables, ingredients, pet food and more.
“We’re excited to be a part of the Duravant group of world-class brands and automation solutions,” said Rolf Michiels, Director of Project Sales. “Aligning with the Fischbein team to better serve our customers through a united and collaborative strategy is an exciting prospect for us. Duravant’s lifecycle management via the company’s SupportPro services also gives our customers broader access to value-added solutions that will help their operations achieve their productivity and efficiency goals.”
The Votech brand of packaging machinery has been a competitive force in filling and bag management for over a decade. Votech’s deep engineering and development capabilities allow for the custom design of complete automated solutions from the filling of a bag, to the internal pallet transport to the warehouse. Recognized for superior engineering, package control and local field service support, Votech has proven success delivering packaging solutions for free-flowing and powders applications.
“Our partnership with Duravant opens the path for Votech’s geographic expansion and growth in Europe, the Middle-East, Africa and North America,” adds Pierre Dierckx, Director of Operations. “We’re thrilled to also collaborate with nVenia, Duravant’s US-based operating company serving customers across a wide array of industrial end markets and consumer packaged goods.” The Votech solution set for powders applications is highly complementary with the nVenia product range across primary, secondary and end-of-line packaging.
About Duravant
Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales and service facilities throughout North America, Europe and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end process solutions for customers and partners through engineering and integration expertise, project management and operational excellence. With worldwide sales distribution and service networks, they provide immediate and lifetime aftermarket support to all the markets they serve in the food processing, packaging and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability and reliability. For more information, visit www.duravant.com .
About Votech
Headquartered in Reusel, The Netherlands, Votech specializes in developing bag filling and palletizer machines, stretch hood machines and transport systems. The Votech brand has been recognized for providing complete packaging lines from the filling of a bag, through to the internal pallet transport to the warehouse. The entire Votech equipment portfolio is available through Fischbein, a Duravant Company. For more information, visit www.votechbv.co.uk .
About Fischbein
Fischbein designs and manufactures bag packaging equipment and complete systems. For over 100 years, Fischbein has been the leader in sewing and sealing systems by delivering highly engineered, robust and dependable solutions. Serving customers worldwide in agriculture, animal feed, seed, pet food, chemical, mineral, milling, food, building material, medical and pharmaceutical industries, Fischbein has a full range of sealing, filling, weighing, handling, and palletizing equipment that is sold and serviced in more than 190 countries. Fischbein is a Duravant Company. For more information, visit www.fischbein.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005061/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
